Viewing Study NCT05320692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:35 PM
Ignite Modification Date: 2026-02-23 @ 8:57 PM
Study NCT ID: NCT05320692
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-11
First Post: 2022-04-02
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hepatocellular Carcinoma View
Keywords: